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 Materials.  All chemical reagents were obtained from commercial suppliers, and used 
without further purification unless otherwise stated. NHS-LC-biotin and O-GlcNAcylated 
model peptide TAPT(gS)TIAPG were purchased from Thermo Scientific. OGA inhibitor 
ThiaMet-G was obtained from Tocris Bioscience. Site-directed mutagenesis kit was 
purchased from Agilent Technologies. All other reagents were obtained from Sigma-
Aldrich.  
 
Synthesis of the isotope-labeled photocleavable probes 1 (1H7) and 1d (2D7). 
 
 
 
 
1-(2-nitro-5-((6-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)hexanamido)methyl)phenyl)ethyl ((S)-1-(but-3-yn-1-ylamino)-4-
methyl-1-oxopentan-2-yl)carbamate (1). 1-(5-(Aminomethyl)-2-nitrophenyl)ethanol (2) 
was synthesized as previously described in literature1. To a solution of NHS-LC-biotin 
(250 mg, 0.55 mmol) in DMF (8 mL), compound 2 (131 mg, 0.67 mmol) was added 
followed by triethylamine (115 µL, 0.82 mmol). The reaction was stirred at room 
temperature for overnight. The solvent was removed under reduced pressure, and the 
residue was purified by flash silica gel chromatography (CH2Cl2/CH3OH 10:1) to afford 
the conjugate (206 mg, 70%). m/z calcd for C25H38N5O6S [M + H]+: 536.2537. MS 
found: 536.2. The conjugate (200 mg, 0.37 mmol) was redissolved in DMF (10 mL) and 
N,N’-disuccinimidyl carbonate (143 mg, 0.56 mmol) and triethylamine (155 µL, 1.11 
mmol) were added. After stirring for overnight, L-leucinylbuty-nylamide (4) (337 mg, 
 1.85 mmol) was added and the reaction mixture was stirred at room temperature for 
another 24 h. Upon completion, the solvent was removed under reduce pressure and the 
residue was purified by flash silica gel chromatography (CH2Cl2/CH3OH 10:1) to afford 
the target compound (1) (150 mg, 54%). 1H NMR (400 MHz, DMSO-d6), δ (ppm): 8.43 
(m, 1H), 8.03-7.94 (m, 2H), 7.74 (t, J = 5.6 Hz, 1H), 7.58 (d, J = 20.8 Hz, 1H), 7.45 (m, 
1H), 7.36 (d, J = 8.4 Hz, 1H), 6.41 (s, 1H), 6.35 (s, 1H), 6.02-5.96 (m, 1H), 4.39-4.29 (m, 
3H), 4.12 (m, 1H), 3.84 (m, 1H), 3.17-3.00 (m, 5H), 2.81 (m, 2H), 2.58 (d, J = 13.2 Hz, 
1H), 2.18 (m, 4H), 2.04 (m, 2H), 1.68-1.22 (m, 18 H), 0.85 (m, 5H), 0.70 (m, 1H). m/z 
calcd for C36H54N7O8S [M + H]+: 744.3749. MS found: 744.3 (M + H). The deuterated 
compound 1d was synthesized following the same procedure described above using the 
deuterated leucine derivative (4d). 1H NMR (400 MHz, DMSO-d6), δ (ppm): 8.42 (m, 
1H), 8.02 (m, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.74 (m, 1H), 7.55 (s, 1H), 7.43 (d, J = 8.4 
Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 6.41 (s, 1H), 6.35 (s, 1H), 5.97 (m, 1H), 4.35-4.28 (m, 
3H), 4.14-4.11 (m, 1H), 3.83 (m, 1H), 3.17 (m, 2H), 3.10(m, 2H), 3.01 (m, 2H), 2.80 (m, 
2H), 2.57 (d, J = 13.2 Hz, 1H), 2.26 (m, 2H), 2.17 (m, 2H), 2.06-2.02 (m, 2H), 1.58-1.22 
(m, 16H). m/z calcd for C36H47D7N7O8S [M + H]+: 751.4188. MS found: 751.4 (M + H). 
N-Fluorenylmethyloxycarbonyl-L-leucinylbuty-nylamide (3). 3-Butynylamine (95% 
purity, 0.52 ml, 6.0 mmol) was added to N-Fmoc-L-leucine (1414 mg, 4.0 mmol) and 
HATU (1673 mg, 4.4 mmol) in DMF (12 mL) at room temperature under nitrogen. The 
solution was cooled on ice and triethylamine (1.67 mL, 12 mmol) was added, the reaction 
mixture was then allowed to reach room temperature and stirred for 24 h. Upon 
completion, the reaction mixture was diluted with EtOAc (100 ml), washed with 0.1 M 
HCl (2 × 30 ml), saturated NaHCO3 (30 ml), brine (50 ml), dried over anhydrous Na2SO4 
and the solvents were removed under reduced pressure. The residue was purified by flash 
silica gel chromatography (hexane/EtOAc 1:1). N-Fluorenylmethyloxycarbonyl-L-
leucinylbuty-nylamide (3) was afforded as a white solid (880 mg, 2.18 mmol, 54%). 1H 
NMR (400 MHz, CDCl3), δ (ppm): 7.77 (d, J = 7.6 Hz, 2H), 7.58 (d, J = 7.6 Hz, 2H), 
7.41 (m, 2H), 7.32 (m, 2H), 6.27 (brs, 1H), 5.17 (d, J = 7.6 Hz, 1H), 4.43 (m, 2H), 4.21 
(m, 2H), 3.40 (m, 2H), 2.39 (brs, 2H), 1.96 (s, 1H), 1.63 (m, 3H), 0.94 (s, 6H).  
L-Leucinylbuty-nylamide (4). A 20% (v/v) solution of piperidine in DMF (20 mL) was 
added to a residue of (3) (780 mg, 1.93 mmol). After 10 min, a precipitate formed and 3 
 mL DMF was added to the mixture. After 30 minutes, volatiles were removed reduced 
pressure. H2O was added to the residue and the mixture was stirred vigorously and then 
stored in the refrigerator overnight. The precipitate was removed via filtration, and 
washed with cold H2O. The aqueous layer was extracted CH2Cl2 (3 × 50 mL) and EtOAc 
(3 × 50 mL). The combined organic layers were dried over Na2SO4 and concentrated to 
provide leucine derivative (4) 240 mg (1.32 mmol, 68%). 1H NMR (400 MHz, CDCl3), δ 
(ppm): 7.60 (brs, 1H), 3.41-3.35 (m, 3H), 2.40-2.36 (m, 2H), 1.99 (t, J = 2.8 Hz, 1H), 
1.70-1.67 (m, 2H), 1.47 (s, 2H), 1.33 (t, 1H), 0.91 (m, 6H). The deuterated leucine 
derivative 4d was synthesized following the same procedure described above. 
 
Labeling and quantification of model O-GlcNAcylated peptide. 20 µg of O-
GlcNAcylated peptide (H-Thr-Ala-Pro-Thr-(O-GlcNAc)Ser-Thr-Ile-Ala- Pro-Gly-OH) 
was dissolved in 20 mM HEPES pH 7.9, and labeled using the Click-iT O-GlcNAc 
Enzymatic Labeling System (Invitrogen) for 2 h at 37˚C. The reaction mixture was then 
filtered through a 2000 Da MWCO spin filter and injected into a reverse-phase HPLC 
C18 column (Spherisorb; 5µm, 250 x 4.6 mm). Agilent 1260 HPLC system was used to 
generate the following HPLC gradient: 12-18% B in 10 min, 18-40% B in 3 min, 40-55% 
B in 5 min (A: 0.1% Trifluoroacetic acid, B: Acetonitrile) with a flow rate of 1 mL/min. 
Then the product was separated by HPLC and lyophilized. The GalNAz-labeled O-
GlcNAc peptide was divided equally into two portions, which were conjugated with 1H7 
coded photocleavable probe and 2D7 coded photocleavable probe respectively. The 
CuAAC (the copper(I)-catalyzed azide alkyne cycloaddition, 0.1 mM isotopic coded 
probe, 0.25 mM CuSO4, 0.5 mM BTTAA ligand, 2.5 mM sodium ascorbate) was 
proceeded for 2 h at room temperature in the dark. Then the isotope-labeled peptide 
mixtures were combined and purified by HPLC using the conditions described above, 
and lyophilized. The purified isotope-labeled O-GlcNAc peptides were dissolved in the 
binding buffer (100 mM phosphate buffer, pH 7.2, 150 mM NaCl), and incubated with 
streptavidin resins (Pierce) with end-to-end rotation for 2 h at room temperature in the 
dark. Resins were washed with 1 mL of Milli-Q water for 5 times, 70% methanol twice, 
and then resuspended in 70% methanol. The bound glycopeptides were released from 
resins by UV (365 nm) irradiation for 1 h. The supernatant was collected and analyzed by 
 HPLC and further quantified by electron-transfer/higher-energy collision dissociation 
(EThcD) based MS/MS as described below.  
 
Cell culture and lysate preparation. The cell lines 293T, MCF-7, HepG2, and A549 
were obtained from ATCC and cultured according to ATCC protocols. Adriamycin-
resistant MCF-7 cells, sorafenib-resistant HepG2 cells, and docetaxel-resistant A549 cells 
were obtained from GeneChem LLC, China, and independently verified using laboratory 
procedures. After cells were collected, cells were washed with cold PBS for three times, 
and lysed on ice with RIPA lysis buffer (50 mM Tris, 150 mM NaCl, 1% (v/v) Nonidet 
P-40, 0.5% sodium deoxycholate, 0.1% (w/v) SDS, pH 7.4) containing EDTA-free 
protease inhibitor cocktail (Roche) and 10 µM ThiaMet-G. After sonication, cell lysates 
were centrifuged at 15,000 g for 15 min at 4 °C. The supernatant was collected and the 
total protein concentration was measured by the BCA protein assay kit (Beyotime 
biotechnology). 
 
Generation of gene expression vectors and mutants. The coding sequences of ZYX, 
ZHX3 (cDNA clones obtained from Genescript) were cloned into p3XFlag-CMV-7.1 
vector (Sigma-Aldrich) to form Flag-ZYX-WT (with the forward primer, 5’-
cccaagcttatggcggccccccgcccgtct-3’, and the reverse primer, 5’-
cgggatcctcaggtctgggctctagcagt-3’), Flag-ZHX3-WT (with the forward primer, 5’-
cccaagcttatggccagcaagaggaaatccacca-3’, and the reverse primer, 5’-
cgggatcctcagtctgtttcgagctgacgtcca-3’) plasmids. Flag-ZYX-S169A (with the forward 
primer, 5’-caaagcccgggtggcatctggatatgtgcccccac-3’, and the reverse primer, 5’-
catatccagatgccacccgggctttgaaaggatc-3’), Flag-ZHX3-S240A (with the forward primer, 5’-
gttccagtcgcccaggcatctgccagctctgc-3’, and the reverse primer, 5’-
gatgcctgggcgactggaactgccccattgatg-3’) mutants were generated using QuikChange II Site 
Directed Mutagenesis Kit (Agilent Technologies).  
 
Western-blotting analysis of O-GlcNAcylated proteins.   Cell lysates were subjected to 
the GalT enzymatic labeling reaction, and further conjugated with an alkyne-biotin 
compound as per the Click-iT Protein Analysis Detection Kit protocol (Invitrogen). 
 Biotinylated lysates were precipitated, resolubilized in 1% SDS, and neutralized with an 
equal volume of neutralization buffer (6% NP-40, 100 mM Na2HPO4, 150 mM NaCl). 
Lysates were then incubated with streptavidin resin (Pierce) with end-to-end rotation at 4 
oC overnight. Resin was then washed 5 times with 1 mL of low salt buffer (100 mM 
Na2HPO4, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 0.5% sodium deoxycholate) and 
5 times with 1 mL of high salt buffer (100 mM Na2HPO4, 500 mM NaCl, 0.2% Triton X-
100). Biotinylated proteins were eluted by boiling the resin in 50 mM Tris-HCl pH 6.8, 
2.5% SDS, 100 mM DTT, 10% glycerol and 20 mM biotin for 10 min. The eluents were 
then resolved on a 4-12% SDS-PAGE gel, transferred to Immobilon-FL PVDF 
membrane (Millipore), and immunoblotted with the indicated antibodies. 
 
Quantification of protein O-GlcNAcylation in 293T cell lysates. 293T cell treated with 
DMSO or TMG (50 μM for 12 hours) were harvested as above-mentioned. 4 mg of total 
protein mixtures from each sample were chemoenzymatic labeled as above. To eliminate 
the impact of N-glycan, PNGase F (New England Biolabs) was added in the labeling 
buffer. The labeled proteins were dissolved in 1% SDS (in 50 mM Tris-HCl pH 8.0), and 
conjugated with 1H7 labeled and 2D7 labeled probes, respectively. The reaction mixture 
was incubated for 2 h at room temperature with gentle agitation in the dark. Then the two 
portions (1:1) were mixed together, and precipitated using methanol and chloroform as 
described in the Click-iT Protein Analysis Detection Kit. The labeled proteins were 
solubilized in 800 µL 8M urea, diluted to 10-fold volume with 50 mM NH4HCO3, pH 
8.1, and further digested with sequencing grade modified trypsin (Promega) at a ratio of 
1:100 trypsin : protein (wt/wt) for 16 h at 37 °C in the dark. The reaction was quenched 
with 0.4% TFA, 2% acetonitrile added, desalted with Sep-Pac Vac tC18 Cartridges 
(Waters), and dried in a vacuum centrifuge. Peptides were dissolved in binding buffer 
(100 mM phosphate buffer, pH 7.2, 150 mM NaCl), and incubated with streptavidin 
resins with end-to-end rotation for 2 h at room temperature in the dark. Resins were 
washed with 1 mL of binding buffer for 10 times, Milli-Q water for 6 times, 20% 
methanol twice, 70% methanol once, and then resuspended in 70% methanol. The 
captured peptides were released from resins by UV irradiation (365 nm) for 1 h. The 
 supernatant was collected, dried in a vacuum centrifuge, and then analyzed by CID and 
ETD based LC-MS/MS as described below.   
 
LC-MS/MS analysis. The labeled peptides were desalted with C18 Zip-Tips (Merck) 
and then loaded on an in-house packed capillary reverse-phase C18 column (15 cm 
length, 100 mM ID x 360 mM OD, 3 mM particle size, 100 A° pore diameter, 
Phenomenex) connected to a Thermo Easy-nLC1000 HPLC system (Thermo Fisher, SJ). 
The samples were analyzed with a 120 min-HPLC gradient from 0% to 100% of buffer B 
(buffer A: 0.1% formic acid in water; buffer B: 0.1% formic acid in 20/80 
water/acetonitrile) at 300 nL/min. Ionization was performed on a Q-Exactive mass 
spectrometer (Thermo Fisher, SJ) via an EASY-Spray ion source. Survey full-scan MS 
spectra (from m/z 300–1800) were acquired in the Orbitrap analyzer at a resolution of 
70,000 at m/z 400 (target value of 1,000,000 ions, maximum injection time 20 ms).  
For CID acquisition, data dependent MS2 scan was acquired with a resolution of 35,000 
at m/z 400 (target value of 500,000 ions, maximum injection time 1,000 ms). The 
activation time was set at 30 ms, the isolation width was 1.5 amu, the normalized 
activation energy was 35%, and the activation q was 0.25. Ions with unassigned charge 
state, and singly or highly (> 8) charged ions were rejected. Intensity threshold was set to 
2.1 × 104 units. Peptide match was set to preferred and dynamic exclusion option was 
enabled (exclusion duration 40 s). 
MS2 experiments by ETD were conducted on an Orbitrap Elite mass spectrometer 
(Thermo Scientific) equipped with a nano-ESI source. The mass spectrometer was 
programmed to record a full-scan ESI mass spectrum (m/z = 300-1700) followed by four 
data-dependent MS/MS scans (70-100 ms ETD activation; 2 Da isolation window). The 
normalized activation energy and the activation q were set same with CID method.  
MS2 experiments by EThcD were conducted on an Orbitrap Fusion Lumos (Thermo 
Scientific) mass spectrometer equipped with a Nano-Spray ion source. Survey full-scan 
MS spectra (from m/z 350–1800) were acquired in the Orbitrap analyzer at a resolution 
of 60,000 (target value of 400,000 ions, maximum injection time 50 ms). EThcD was 
activated and calibrated charge dependent ETD parameters were used. Isolation window 
was set at 2 Da.  
  
LC-MS/MS data analysis. CID mass spectrometric raw data files were processed with 
MASCOT against the Uniprot human database; Mass tolerance was set to be 20 ppm for 
precursor and 0.5 Da for product ion. Missed cleavages were no more than two for each 
peptide. O-GlcNAc-tag adduction to Serine (Ser) and Threonine (Thr), and Oxidation 
(Met), Acetyl (N terminus) were set as variable modifications; Carbamidomethyl (Cys) 
was chosen as a fixed modification. The identification data were filtered to a 1% false 
discovery rate (FDR) on both peptide and protein level using target-decoy strategy. MS2 
spectra of tagged peptides were manually validated and annotated based on following 
criteria: (a) good coverage of y-and b-ion series, (b) extensive identification rate of 
intensive fragment ion peaks, (c) the probability of site localization was checked to be 
greater than 75%, and (d) Existence of a diagnostic peak corresponding to a fragment ion 
of photocleaved GalNAz moiety (349.2 Da or 427.2 Da for 1H7 coded, 356.2 Da or 434.3 
Da for 2D7 coded) or an identification of both light- and heavy-labeled peptides 
corresponding to the same O-GlcNAc-tag site. ETD raw data files were processed with 
MaxQuant software integrated with Andromeda search engine against the Uniprot human 
database. The parameters were set as CID data processing. For quantification, the 
intensity of labeled peptides was represented by the peak area of the extracted ion 
chromatogram of their monoisotopic peaks. 
 
Quantification of O-GlcNAcylated peptides in sorafenib -sensitive and -resistant 
HepG2 cells. 4 mg cell lysates of each sample (-sensitive or -resistant) were 
chemoenzymatically labeled, conjugated with 1H7 coded and 2D7 coded probes, 
respectively, and further treated for CID and ETD based MS/MS analysis according to 
the protocols shown above. 
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C., Schuman, E. M., and Tirrell, D. A. (2010). Cleavable Biotin Probes for Labeling of Biomolecules 
via Azide-Alkyne Cycloaddition. J. Am. Chem. Soc., 132, 18351-18360. 
 
  
 
 
 
Figure S1. Labeling and quantification of a model O-GlcNAcylated peptide. (A) 
Glycopeptides were chemo-enzymatically tagged with GalNAz and the isotope-coded 
probes. Equal amounts of the isotopically labeled peptides were combined, affinity 
captured with streptavidin, and further subjected to UV photocleavage. (B) The reaction 
progress was monitored using liquid chromatography, and (C) relative quantification of 
O-GlcNAcylated peptide pairs was performed using an orbitrap mass spectrometry. 
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Figure S2. Fragment spectra of isotopically labeled CREB glycopeptides dissociated by 
EThcD. (A) 1H7 coded and (B) 2D7 coded probe exhibited the same site localization and 
similar fragment spectra, where S5 was the O-GlcNacylated site in both spectra. HCD 
dissociation results loss of tagged GlcNAc moiety and the corresponding characteristic 
oxonium ions. 349.2 Da, 427.2 Da for 1H7 labeled (A), and 356.2 Da, 434.3 Da for 2D7 
labeled (B). 
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Figure S3. Global O-GlcNAc levels in 293T cells treated with or without OGA inhibitor 
TMG. Cells were treated with DMSO (control) or 50 µM TMG for 12 h in the culture 
medium, and were collected and lysed by RIPA lysis buffer. Whole cell lysates were 
separated by SDS-PAGE and immunoblotted with a pan-anti-O-GlcNAc antibody (RL2). 
 
                                    
                                      
 
 
Figure S4. Immunoblotting analysis of O-GlcNAc levels in selected proteins treated with 
or without TMG. O-GlcNAcylated proteins from 293T cell lysates treated with or 
without TMG were chemoenzymatically tagged and conjugated with the probe 1. 
Following affinity capturing and photocleavage, the eluents were immunoblotted with 
antibodies for specific proteins and the changes in O-GlcNAcylation were quantified 
based on the relative amounts of proteins released from the affinity beads. 
 
 
  
  
 
 
Figure S5. O-GlcNAcylation site(s) mapping of selected proteins using ETD-based 
MS/MS, followed by site-directed mutagenesis and immunoblotting analysis. 
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Figure S6. O-GlcNAc levels in drug -sensitive and -resistance cell lines. 
 
 
  
 Table S1. Quantified glycopeptides with CID and ETD from 293T cells cultured in the 
presence or absence of TMG. 
Sheet 1. Quantified glycopeptides with CID from 293T cells. 
Sheet 2. Quantified glycopeptides with ETD from 293T cells. 
Sheet 3. Glycopeptides taken more than1.5-fold increase upon TMG treatment. 
Sheet 4. Glycopeptides taken more than 1.5-fold decrease upon TMG treatment. 
Sheet 5. Glycopeptides taken no measurable change upon TMG treatment. 
 
Table S2. Identification of O-GlcNAcylation sites by ETD from control and TMG 
treated 293T cells. 
Sheet 1. Unambiguously identified O-GlcNAcylation sites from control 293T 
cells. 
Sheet 2. Unambiguously identified O-GlcNAcylation sites from TMG treated 
293T cells. 
 
Table S3. Quantified glycopeptides with CID and ETD from sorafenib-sensitive and -
resistant HepG2 cells. 
Sheet 1. Quantified glycopeptides with CID from HepG2 cells. 
Sheet 2. Quantified glycopeptides with ETD from HepG2 cells. 
Sheet 3. Glycopeptides taken more than1.2-fold increase in sorafenib-resistant 
HepG2 cells compared with its sensitive counterparts. 
Sheet 4. Glycopeptides taken more than 1.2-fold decrease in sorafenib-resistant 
HepG2 cells compared with its sensitive counterparts. 
 
Table S4. Identification of O-GlcNAcylation sites by ETD from sorafenib-sensitive and -
resistant HepG2 cells. 
 
